Background: Sarcoidosis is a multisystem inflammatory disease of uncertain etiology that is histopathologically characterized by non-necrotizing granulomas. It typically involves the lungs and lymph nodes, but has been reported in many other organ systems as well. Sarcoidosis involving the female genital tract, the uterus in particular, is a rare event with isolated accounts in the medical literature. Case: We present a rare occurrence of cervical sarcoidosis in a Pap test of a 31-year-old woman with a history of biopsy-proven mediastinal lymph node sarcoidosis and mediastinal pleomorphic liposarcoma with status post chemotherapy. The Surepath smear showed crowded cellular groups with abundant epithelioid histiocytes and lymphocytes consistent with granulomatous inflammation. No granular necrotic debris or polarizable foreign body material was identified. There were no microorganisms present. The cytomorphologic features and differential diagnoses are discussed. Conclusion: Uterine cervical sarcoidosis, although rare, can be an overlooked cause of non-necrotizing granulomatous inflammation in a cervical Pap test. Sarcoidosis should be a diagnosis of exclusion; other common conditions with similar morphologic presentation such as non-necrotizing tuberculosis, foreign body-related granulomatous inflammation, and neoplastic/chemotherapy-related sarcomatoid reaction need to be excluded in conjunction with the patient’s clinical history.

Keywords:
Cervical, Cytopathology, Sarcoidosis, Pap test
1.
Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 2003;289:3300–3303.
2.
Spaun E, Nielsen K: Sarcoidosis of the endometrium. Ugeskr Laeger 1983;145:2308.
3.
Skehan M, McKenna P: Sarcoidosis of the endometrium: a case presentation. Ir J Med Sci 1985;154:114.
4.
DiCarlo FJ Jr, DiCarlo JP, Robboy SJ, Lyons MM: Sarcoidosis of the uterus. Arch Pathol Lab Med 1989;113:941–943.
5.
Sandvei R, Bang G: Sarcoidosis of the uterus. Acta Obstet Gynecol Scand 1991;70:165–167.
6.
Pietinalho A, Hiraga Y, Hosoda Y, Lofroos AB, Yamaguchi M, Selroos O: The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995;12:61–67.
7.
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885–1889.
8.
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC: Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234–241.
9.
Taylor AB: Sarcoidosis of the uterus. J Obstet Gynaecol Br Emp 1960;67:32–35.
10.
Ho KL: Sarcoidosis of the uterus. Hum Pathol 1979;10:219–222.
11.
Pearce KF, Nolan TE: Endometrial sarcoidosis as a cause of postmenopausal bleeding. A case report. J Reprod Med 1996;41:878–880.
12.
Almoujahed MO, Briski LE, Prysak M, Johnson LB, Khatib R: Uterine granulomas: clinical and pathologic features. Am J Clin Pathol 2002;117:771–775.
13.
Brincker H: Sarcoidosis and malignancy. Chest 1995;108:1472–1474.
14.
Brincker H: Solid tumors preceding or following sarcoidosis. Med Pediatr Oncol 1987;15:82–88.
15.
Brincker H, Wilbek E: The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974;29:247–251.
16.
Sybert A, Butler TP: Sarcoidosis following adjuvant high-dose methotrexate therapy for osteosarcoma, Arch Intern Med 1978;138:488–489.
17.
Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Sato A, Hiraishi M, Konishi T: Sarcoid reactions in association with a leiomyosarcoma of the stomach. Am J Gastroenterol 1996;91:2623–2624.
18.
Romer FK, Hommelgaard P, Schou G: Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 1998;12:906–912.
19.
Okada K, Sasaki M, Nanjo H, Ito M, Takahashi S, Itoi E: Benign lesions in cancer patients: case 2. Unusual association of osteosarcoma and sarcoidosis. J Clin Oncol 2005;23:641–643.
20.
Caras WE, Dillard T, Baker T, Pluss J: Coexistence of sarcoidosis and malignancy. South Med J 2003;96:918–922.
21.
Reich JM, Mullooly JP, Johnson RE: Linkage analysis of malignancy-associated sarcoidosis. Chest 1995;107:605–613.
22.
Suen JS, Forse MS, Hyland RH, Chan CK: The malignancy-sarcoidosis syndrome. Chest 1990;98:1300–1302.
23.
Oliwiecki S, Kotecha B, Kingston T, Rothera MP: Sarcoidosis-lymphoma syndrome. J R Soc Med 1992;85:176–177.
24.
Seersholm N, Vestbo J, Viskum K: Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax 1997;52:892–894.
25.
Artinian V, Kvale PA: Cancer and interstitial lung disease. Curr Opin Pulm Med 2004;10:425–434.
26.
Romer FK: Is there any causal relationship between sarcoidosis and malignancy? Sarcoidosis 1990;7:80–82.
27.
Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A: Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999;160:1668–1672.
28.
Yamasawa H, Ishii Y, Kitamura S: Concurrence of sarcoidosis and lung cancer. A report of four cases. Respiration 2000;67:90–93.
29.
Cohen PR, Kurzrock R: Sarcoidosis and malignancy. Clin Dermatol 2007;25:326–333.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.